HC Wainwright & Co. Reiterates Buy on Insmed, Announces $220 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 87.5%

Neg 0% Neu 87.5% Pos 0%

HC Wainwright & Co. analyst Andrew S. Fein reiterates Insmed (NASDAQ:INSM) with a Buy and announces $220 price target.

Comments

No comments yet. Be the first!